ClinicalTrials.gov. Study to evaluate the efficacy, safety and tolerability of PXT002331 (foliglurax) in reducing motor complications of levodopa therapy in Parkinson disease's patients (AMBLED). https://clinicaltrials.gov/ct2/show/NCT03162874. Accessed November 4, 2019.
ClinicalTrials.gov. Efficacy and tolerability of IRL790 in Parkinson's disease dyskinesia. https://clinicaltrials.gov/ct2/show/NCT03368170?term=NCT03368170&rank=1. Accessed November 4, 2019.
Espay A, Ellenbogen A, Oren S, et al. Efficacy of ND0612 for nocturnal problems and early morning OFF: a blinded rater study of 2 dosing regimens (P2.8-052). Neurology. 2019;92(15 Suppl):P2.8-052.
Garrido A, Fairfoul G, Tolosa ES, et al. α-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease. Ann Clin Transl Neurol. 2019;6:1024-1032.
LeWitt P, Claassen D, Olson K, et al. Once-daily opicapone increases ON-time in patients with Parkinson's disease: results from two phase 3 studies (S4.003). Neurology. 2019;92(15 Suppl):S4.003.
Lipsmeier F, Taylor KI, Postuma RB, et al. Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in recently diagnosed Parkinson patients. Neurology. 2019;92(15 Suppl):P4.7-005.
Marques TM, van Rumund A, Oeckl P, et al. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology. 2019;92:e1479-e1486.
Pagan F, Hebron M, Wilmarth B, et al. Nilotinib safety and clinical effects on "ON" disability in Parkinson's disease patients. Presented at: International Congress of Parkinson's Disease and Movement Disorders; September 22-26, 2019; Nice, France. Abstract LBA 15.
Savitt D, Jankovic J. Targeting α-synuclein in Parkinson's disease: progress towards the development of disease-modifying therapeutics. Drugs. 2019;79:797-810.
Simuni T. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson's disease (STEADY-PD III): final study results. Mov Disord. 2019;34(Suppl 2):S1-S930.
Trenkwalder C, Kuoppamäki M, Vahteristo M, et al. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial. Neurology. 2019;92:e1487-e1496.
Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of levodopa in Parkinson's disease. N Engl J Med. 2019;380:315-324.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Michael S. Okun, MD

Adelaide Lackner Professor
Chairman, Department of Neurology
Executive Director, Norman Fixel Institute for Neurological Diseases
University of Florida Health
Gainesville, Florida

Disclosures

Disclosure: Michael S. Okun, MD, has disclosed no relevant financial relationships.

Panelists

Daniel O. Claassen, MD

Associate Professor of Neurology
Vanderbilt University Medical Center
Nashville, Tennessee

Disclosures

Disclosure: Daniel O. Claassen, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc.; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Teva Pharmaceuticals USA; Vertical Pharmaceuticals Inc.
Received grants for clinical research from: AbbVie Inc.; Lundbeck, Inc.; Genentech, Inc.; Neurocrine Biosciences, Inc.; Roche; Vaccinex

Joohi Jimenez-Shahed, MD

Associate Professor of Neurology and Medical Director, Movement Disorders Neuromodulation and Brain Circuit Therapeutics
Chair of the Functional Neurosurgical Working Group of the Parkinson Study Group
The Mount Sinai Health Network
New York, New York

Disclosures

Disclosure: Joohi Jimenez-Shahed, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Amneal; Boston Scientific; Bracket; Medtronic, Inc.; Nuvelution; Revance; Revance; St. Jude Medical; Teva Pharmaceuticals USA
Received grants for clinical research from: Abbott Laboratories; Lilly; Medtronic, Inc.; Sunovion Pharmaceuticals Inc.; Teva Pharmaceuticals USA

Editor

Lisette Arnaud-Hevi, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisette Arnaud-Hevi, PhD, has disclosed no relevant financial relationships.

Anita A. Galdieri, PharmD, RPh

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Anita A. Galdieri, PharmD, RPh, has disclosed no relevant financial relationships.

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Updates in Parkinson Disease 2019: A Year in Review

Authors: Michael S. Okun, MD; Joohi Jimenez-Shahed, MD; Daniel O. Claassen , MD
CME / ABIM MOC Released: 11/26/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/26/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for neurologists, primary care physicians, and orthopedists.

The goal of this activity is to inform HCPs of the latest developments in biomarkers and treatment research for PD

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data pertaining to the diagnosis of Parkinson disease (PD)
- Data for therapies being studied for the management of PD

Disclosures

Moderator

Michael S. Okun, MD

Adelaide Lackner Professor
Chairman, Department of Neurology
Executive Director, Norman Fixel Institute for Neurological Diseases
University of Florida Health
Gainesville, Florida

Disclosures

Disclosure: Michael S. Okun, MD, has disclosed no relevant financial relationships.

Panelists

Daniel O. Claassen, MD

Associate Professor of Neurology
Vanderbilt University Medical Center
Nashville, Tennessee

Disclosures

Disclosure: Daniel O. Claassen, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc.; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Teva Pharmaceuticals USA; Vertical Pharmaceuticals Inc.
Received grants for clinical research from: AbbVie Inc.; Lundbeck, Inc.; Genentech, Inc.; Neurocrine Biosciences, Inc.; Roche; Vaccinex

Joohi Jimenez-Shahed, MD

Associate Professor of Neurology and Medical Director, Movement Disorders Neuromodulation and Brain Circuit Therapeutics
Chair of the Functional Neurosurgical Working Group of the Parkinson Study Group
The Mount Sinai Health Network
New York, New York

Disclosures

Disclosure: Joohi Jimenez-Shahed, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Amneal; Boston Scientific; Bracket; Medtronic, Inc.; Nuvelution; Revance; Revance; St. Jude Medical; Teva Pharmaceuticals USA
Received grants for clinical research from: Abbott Laboratories; Lilly; Medtronic, Inc.; Sunovion Pharmaceuticals Inc.; Teva Pharmaceuticals USA

Editor

Lisette Arnaud-Hevi, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisette Arnaud-Hevi, PhD, has disclosed no relevant financial relationships.

Anita A. Galdieri, PharmD, RPh

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Anita A. Galdieri, PharmD, RPh, has disclosed no relevant financial relationships.

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Neurology & Neurosurgery

CME / ABIM MOC

Updates in Parkinson Disease 2019: A Year in Review

Authors: Michael S. Okun, MD; Joohi Jimenez-Shahed, MD; Daniel O. Claassen , MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 11/26/2019

Valid for credit through: 11/26/2020

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Michael S. Okun, MD

Panelists

Daniel O. Claassen, MD

Joohi Jimenez-Shahed, MD

Editor

Lisette Arnaud-Hevi, PhD

Anita A. Galdieri, PharmD, RPh

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

CME / ABIM MOC

Updates in Parkinson Disease 2019: A Year in Review

Target Audience and Goal Statement

Disclosures

Moderator

Michael S. Okun, MD

Panelists

Daniel O. Claassen, MD

Joohi Jimenez-Shahed, MD

Editor

Lisette Arnaud-Hevi, PhD

Anita A. Galdieri, PharmD, RPh

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Updates in Parkinson Disease 2019: A Year in Review

Educational Impact Challenge